Asia-Pacific indapamide market is estimated to grow significantly at a CAGR of around 3.8% during the forecast period owing to the increasing prevalence of chronic disorders, including hypertension, CVD, and diabetes. The rising incidences of these diseases have been reported in several countries of Asia-Pacific, including China, India, and Singapore. For instance, in India, one in five young adults has high blood pressure, according to the data presented at the 70th Annual Conference of the Cardiological Society of India (CSI) held from November 22nd- 25th 2018. This equals to nearly 80 million adults, which is a significant proportion than the entire UK population. The risk factors for high blood pressure in the country were smoking, tobacco chewing, diabetes mellitus, and high cholesterol. This, in turn, increased the need for hypertension treatment in the region and further encourages the market growth.

Request a Free Sample of our Asia-Pacific Indapamide Market: https://www.omrglobal.com/request-sample/asia-pacific-indapamide-market

The Asia-Pacific indapamide market is segmented on the basis of product and application. Based on product, the market is bifurcated into 1.25 mg and 2.5 mg. Among these, the market for 1.25 mg medicine held the significant market share owing to the extensive application of the drug in treating high blood pressure or hypertension. Based on the application, the market is segmented into high blood pressure, heart failure, and others. The high blood pressure segment is projected to have significant share in the market. Growing incidence of hypertension is contributing to market growth as indapamide drugs are significantly used to treat hypertension while reducing the risk of developing serious heart conditions.

A full Report of Asia-Pacific Indapamide Market is Available at: https://www.omrglobal.com/industry-reports/asia-pacific-indapamide-market

Asia-Pacific Indapamide Market Segmentation

By Product

• 1.25 MG
• 2.5 MG

By Application

• High Blood Pressure
• Heart Failure
• Others

Regional Analysis

• China
• India
• Japan
• Rest of Asia-Pacific

Company Profiles

• ANI Pharmaceuticals, Inc.
• Glenmark Pharmaceuticals Ltd.
• Merck KGaA
• Sandoz International GmbH
• Sanofi S.A.
• Shandong Yinfeida Pharmaceutical Co., Ltd.
• Supra Chemicals
• Suzhou Lixin Pharmaceutical Co., Ltd.
• Taj Pharmaceuticals Ltd.
• Torrent Pharmaceuticals Ltd.

For More Customized Data, Request for Report Customization @ https://www.omrglobal.com/report-customization/asia-pacific-indapamide-market

About Orion Market Research

Orion Market Research (OMR) is a market research and consulting company known for its crisp and concise reports. The company is equipped with an experienced team of analysts and consultants. OMR offers quality syndicated research reports, customized research reports, consulting and other research-based services.

For More Information, Visit Orion Market Research

Media Contact:
Company Name: Orion Market Research
Contact Person: Mr. Anurag Tiwari
Email: [email protected]
Contact no: +91 7803040404